Literature DB >> 8727442

The outcome of children admitted to intensive care with meningococcal septicaemia.

Q Mok1, W Butt.   

Abstract

OBJECTIVE: To review our experience of children with meningococcal septicaemia, and to validate, in our group, severity scores used in different populations to predict outcome.
DESIGN: Retrospective review of case notes and charts. PATIENTS: A total of 35 children were admitted to the paediatric intensive care unit (ICU) in the Royal Children's Hospital (RCH) in the 8 years between January 1985 and December 1992 with proven meningococcal septicaemia.
RESULTS: Ages ranged from 4 months to 16 years, with a median age of 20 months. The median meningococcal score was 4 and the median PRISM score was 20, with scores above these being significantly associated with death (P < 0.0001). Thirty-two children (91%) received infusions of colloid for hypovolaemia and twenty-nine (83%) received one or more inotropic drugs. Twenty-one children (60%) required mechanical ventilation for a median of 16.5 h (range 7-574). Seven children (20%) underwent plasmapheresis. Six children (17%) underwent haemofiltration and two (6%), peritoneal dialysis. One patient received extracorporeal membrane oxygenation (ECMO) because of circulatory failure. Twenty-one children (60%) developed disseminated intravascular coagulation, renal failure and/or skin or limb necrosis. The overall survival was 66%, and all survivors are functionally normal.
CONCLUSION: The mortality from the disease remains at 34% despite the technological advances in intensive care. The PRISM and meningococcal scores are useful in predicting outcome. Novel methods of treatment (e.g., plasmapheresis or ECMO) may be valuable.

Entities:  

Mesh:

Year:  1996        PMID: 8727442     DOI: 10.1007/BF01712247

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  Increase in admissions for Neisseria meningitidis infection in Australia.

Authors:  D A Clements; G L Gilbert
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

2.  Pediatric risk of mortality (PRISM) score.

Authors:  M M Pollack; U E Ruttimann; P R Getson
Journal:  Crit Care Med       Date:  1988-11       Impact factor: 7.598

3.  Plasmapheresis for fulminant meningococcemia.

Authors:  M S Drapkin; J S Wisch; J A Gelfand; J G Cannon; C A Dinarello
Journal:  Pediatr Infect Dis J       Date:  1989-06       Impact factor: 2.129

4.  Prognostic Factors in meningococcal disease.

Authors:  P M Niklasson; P Lundbergh; T Strandell
Journal:  Scand J Infect Dis       Date:  1971

5.  Tumour necrosis factor alpha antibody protects against lethal meningococcaemia.

Authors:  X Nassif; J C Mathison; E Wolfson; J A Koziol; R J Ulevitch; M So
Journal:  Mol Microbiol       Date:  1992-03       Impact factor: 3.501

6.  Plasma and whole blood exchange in meningococcal sepsis.

Authors:  M van Deuren; F W Santman; R van Dalen; R W Sauerwein; L F Span; J W van der Meer
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

7.  Extracorporeal membrane oxygenation for refractory septic shock in children.

Authors:  J Beca; W Butt
Journal:  Pediatrics       Date:  1994-05       Impact factor: 7.124

8.  Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group.

Authors:  E Girardin; P Roux-Lombard; G E Grau; P Suter; H Gallati; J M Dayer
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

9.  Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987.

Authors:  P L Havens; J S Garland; M M Brook; B A Dewitz; E S Stremski; T J Troshynski
Journal:  Pediatr Infect Dis J       Date:  1989-01       Impact factor: 2.129

10.  Blood filtration in children with severe sepsis: safe adjunctive therapy.

Authors:  J H Reeves; W W Butt
Journal:  Intensive Care Med       Date:  1995-06       Impact factor: 17.440

View more
  8 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

2.  Mortality in severe meningococcal disease.

Authors:  K Thorburn; P Baines; A Thomson; C A Hart
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Neurodevelopmental outcome in meningococcal disease: a case-control study.

Authors:  J M Fellick; J A Sills; O Marzouk; C A Hart; R W Cooke; A P Thomson
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

5.  Purpura fulminans in meningococcal septicaemia in an adult: a case report.

Authors:  D Bollero; M Stella; E N Gangemi; L Spaziante; J Nuzzo; G Sigaudo; F Enrichens
Journal:  Ann Burns Fire Disasters       Date:  2010-03-31

6.  Two cases of meningococcal purpura fulminans: the 'less is more' approach.

Authors:  Zeeshan Ahmad; Robert Jordan; Rana Das-Gupta; Shekhar Srivastava
Journal:  Int Wound J       Date:  2013-01-17       Impact factor: 3.315

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

Review 8.  Clinical review: extracorporeal blood purification in severe sepsis.

Authors:  Ramesh Venkataraman; Sanjay Subramanian; John A Kellum
Journal:  Crit Care       Date:  2003-02-21       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.